Home > Insider Trading > Filing (0000890465-13-000015)

Filing Details

Accession Number:: 0000890465-13-000015
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-09-04 21:33:43
Reporting Period:: 2013-08-30

Filing Date:: 2013-09-04
Accepted Time:: 2013-09-04 21:33:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1451767	Roger Garceau	550 Hills Drive Bedminster NJ 07921	Svp & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-08-30	74,242	$3.34	138,388	No	4	M	Direct
Common Stock	Acquisiton	2013-08-30	9,375	$5.98	147,763	No	4	M	Direct
Common Stock	Acquisiton	2013-08-30	26,383	$8.25	174,146	No	4	M	Direct
Common Stock	Disposition	2013-08-30	110,000	$25.18	64,146	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2013-08-30	1,622	$0.00	1,622	$3.34
Common Stock	Stock Options	Disposition	2013-08-30	12,620	$0.00	12,620	$3.34
Common Stock	Stock Options	Disposition	2013-08-30	60,000	$0.00	60,000	$3.34
Common Stock	Stock Options	Disposition	2013-08-30	9,375	$0.00	9,375	$5.98
Common Stock	Stock Options	Disposition	2013-08-30	26,383	$0.00	26,383	$8.25

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,378	2020-02-19	No	4	M	Direct
27,380	2020-02-19	No	4	M	Direct
20,000	2020-02-19	No	4	M	Direct
0	2018-12-11	No	4	M	Direct
28,617	2021-02-17	No	4	M	Direct

Footnotes

The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective May 22, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $25.00 and $25.64. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On November 7, 2011, the performance criteria for 10,000 of these options had been satisfied because the Issuer's Phase 3 pivotal study of NPSP558 had met the primary efficacy endpoint of a 50 percent or greater reduction in oral calcium supplementation and active vitamin D therapy and a total serum calcium concentration that was normalized or maintained compared to baseline after 24 weeks of treatment. These 10,000 options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. As of the date of this filing, 7,500 of the 10,000 options have vested.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On January 30, 2012, the performance criteria for 40,000 of these options had been satisfied because the Issuer's NDA was accepted by the FDA. These 40,000 options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. As of the date of this filing, 30,000 of the 40,000 options have vested.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On December 21, 2012, the performance criteria for 80,000 of these options was satisfied when the FDA unanimously voted to approve the NDA for GATTEX for the treatment of SBS. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. As of the date of this filing, 60,000 of the 80,000 options have vested.
Stock options granted under the 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, all of the 150,000 options granted on December 11, 2008 have vested.
Stock options granted under the 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 34,374 of the 55,000 options granted on February 17, 2011 have vested.